What it is
This is a combination pill holding two compounds at fixed amounts: 250 mcg of SLU-PP-332 and 6 mg of orforglipron. A mcg is a microgram, one thousandth of a milligram (mg).
SLU-PP-332 is a small molecule studied as an "exercise mimetic" — a compound that switches on some of the same processes inside your cells that physical exercise switches on, particularly the building of more mitochondria, the tiny structures inside cells that turn food into usable energy.
Orforglipron is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it tells the pancreas to release insulin, slows how fast the stomach empties, and signals fullness to the brain. An "agonist" is a compound that switches a receptor on, so orforglipron mimics that hormone. What makes it unusual is that it is a small molecule you can swallow — most GLP-1 compounds are peptides that must be injected, because the gut would digest them.
So the pairing is an appetite-suppressing arm and an energy-expenditure arm in one pill: eat less on one side, burn more on the other.
Possible side effects and dosing for this blend are covered below. No benefits list, contraindication list, or cycle length has been established for it.
Fixed-ratio oral combination: SLU-PP-332 250 mcg + orforglipron 6 mg per pill.
SLU-PP-332 is a pan-agonist of the estrogen-related receptors (ERRα/β/γ), acting downstream of PGC-1α on mitochondrial biogenesis, oxidative-phosphorylation gene expression, and fatty-acid oxidation.
Orforglipron is a non-peptide, orally bioavailable GLP-1 receptor agonist. Unlike the injectable incretin peptides it is not degraded in the gut, and it carries no food or water-timing restriction on the standalone page on this site. Mechanistically it is glucose-dependent insulinotropic, delays gastric emptying, and produces central satiety signalling.
The combination is a satiety arm plus an expenditure arm. The blend page's dosing structure is driven entirely by the GLP component: the week-1 every-other-day step exists to titrate GLP tolerance, and users with prior GLP exposure skip it.
Note the blend contains 6 mg of orforglipron per pill, the same as one pill on the standalone orforglipron page, but the titration here is much faster — the standalone page starts at a quarter pill (1.5 mg).
What it does
There is no established benefits list for this blend. What is covered here is how to take it and what can go wrong.
The two mechanisms above are what the pill is for: appetite suppression and slower stomach emptying from the orforglipron half, and increased cellular energy burning from the SLU-PP-332 half.
The practical instructions are: take it in the morning; you do not have to be fasted, but taking it fasted will lead to better fat loss; keep your protein intake high; and drink enough water.
The high-protein instruction matters. Rapid weight loss driven by appetite suppression takes muscle as well as fat unless protein intake is kept up.
No benefits list is given. Effects follow from the two components: GLP-1 receptor agonism producing glucose-dependent insulin secretion, delayed gastric emptying, and central satiety; ERR agonism producing increased oxidative capacity and fatty-acid oxidation.
Administration: morning dosing; fasting not required but stated to improve fat-loss outcomes; maintain a high-protein diet and sufficient hydration.
The high-protein instruction is an implicit acknowledgement of the lean-mass loss that accompanies GLP-driven caloric restriction, and the hydration instruction addresses both GLP gastrointestinal fluid loss and the increased expenditure from the ERR arm.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits list has been established for this blend; only side effects and dosing are documented.Anecdotal
- Neither of the two standalone component pages on this site carries a benefits list either, so nothing can be carried across.Anecdotal
- The reason for the combination is the pairing of appetite suppression with increased energy expenditure described above.Animal or lab only
- No benefits are enumerated for the blend, nor for either standalone component entry.Anecdotal
- Class rationale: GLP-1 receptor agonist satiety and glycaemic effects combined with ERR-driven mitochondrial biogenesis and fat oxidation.Animal or lab only
Reconstitution and dosing
Each pill holds 250 mcg of SLU-PP-332 and 6 mg of orforglipron.
If you have never taken any form of GLP compound: week 1 is one pill every other day — days 1, 3, 5, and 7.
If you have taken any form of GLP at any point in the past: skip week 1 and start at week 2.
Weeks 2 to 10: one pill every day, as long as you are not having substantial side effects.
Week 11 onwards: two pills every day.
Take it in the morning. You do not have to be fasted, but fasted dosing gives better fat loss. Keep your protein intake high and drink enough water.
No cycle length or washout period has been set for this blend — unusual for this site, where nearly every entry specifies both.
Fixed ratio, 250 mcg SLU-PP-332 + 6 mg orforglipron per pill.
Titration is GLP-driven. GLP-naive users: week 1 at 1 pill every other day (days 1, 3, 5, 7). Prior GLP exposure at any point: skip week 1, begin at week 2. Weeks 2–10: 1 pill daily, conditional on absence of substantial adverse effects. Week 11 onward: 2 pills daily, i.e. 500 mcg SLU-PP-332 + 12 mg orforglipron.
Morning dosing, fasting not required but stated to improve fat loss, high-protein diet and adequate hydration instructed.
No cycle length or washout is specified for this blend, which is a departure from the site's convention and worth flagging: the standalone orforglipron page runs 18–36 weeks on with a matching washout, and the standalone SLU-PP-332 oral page runs 4–8 weeks. The blend's own schedule extends past week 11 with no stated end.
Dose comparison: the 12 mg/day orforglipron ceiling here sits well inside the standalone entry's 1.5–36 mg range, but the titration is far faster — this blend reaches 6 mg/day in week 2 where the standalone protocol takes until week 3, and it starts GLP-experienced users straight at 6 mg. The 500 mcg/day SLU-PP-332 at week 11+ sits inside the standalone oral page's 300–600 mcg range.
Pills — 250 mcg SLU-PP-332 + 6 mg orforglipron per pill
Cycle: Not established — no cycle length or washout period is given for this blend · Frequency: Take in the morning. Fasting is not required, but a fasted dose leads to better fat loss. Maintain a high-protein diet and sufficient hydration
| When | Dose | How often |
|---|---|---|
| Week 1 — only if you have never taken any form of GLP | 1 pill (250 mcg + 6 mg) | every other day (days 1, 3, 5, and 7) |
| Weeks 2–10 (start here if you have taken any form of GLP at any point) | 1 pill (250 mcg + 6 mg) | once per day, so long as you are not experiencing substantial adverse side effects |
| Week 11 onwards | 2 pills (500 mcg + 12 mg) | every day (2 pills daily; whether to split them has not been specified) |
Who should avoid it
- No contraindications have been documented. That is an absence of documentation, not evidence that the pill is safe for everyone.
- One distinction does function as a caution: if you have never taken any form of GLP compound before, you must start with the every-other-day week 1. Only people who have taken a GLP at some point can skip straight to daily dosing.
- From the standalone orforglipron page on this site: that page also carries no contraindication list, but it notes that the sibling GLP pages on this site carry substantial exclusions, several of them class-wide — a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer) or MEN 2 (a genetic syndrome causing tumours in hormone glands), pregnancy, pancreatitis, and severe gastrointestinal disease.
- Do not combine this with another GLP compound. Elsewhere on this site the instruction not to combine GLP medications with each other is stated plainly.
- The SLU-PP-332 pages list no contraindications at all, so nothing covers that half of the pill.
- Talk to a doctor before starting, and go through your full medication list with them.
- No contraindication list has been established. Missing documentation, not a clean profile.
- The only exclusionary rule is GLP-naive status gating the week-1 every-other-day titration; prior GLP exposure at any point permits skipping to week 2.
- From the standalone orforglipron page: it likewise carries no exclusions, but flags that sibling GLP pages on this site list class-wide contraindications — medullary thyroid carcinoma or MEN 2 history, pregnancy, pancreatitis, severe GI disease.
- Avoid concurrent use with another GLP-1/GIP/glucagon-receptor agent; the prohibition on combining GLP medications is stated elsewhere on this site.
- Neither SLU-PP-332 page carries contraindications, so the ERR arm is undocumented.
Side effects
- Nausea.
- Constipation.
- Diarrhoea.
- Heartburn.
- Fatigue, particularly when the dose is going up.
- Increased body temperature.
- Increased sweating.
- Mild insomnia — difficulty sleeping.
- The first four are the familiar gastrointestinal pattern of GLP compounds, while the temperature, sweating, and insomnia items are what you would expect from a compound that raises energy expenditure. No item has been attributed to one half of the pill or the other.
- The standalone orforglipron entry has no side-effect list, so nothing is available to compare against for that half.
- Nausea.
- Constipation.
- Diarrhoea.
- Heartburn.
- Fatigue, particularly during dose increases.
- Increased body temperature.
- Increased sweating.
- Mild insomnia.
- The GI cluster and titration-linked fatigue map onto the GLP arm; thermogenic and sleep-disruptive items map onto the ERR arm. No formal attribution has been made.
- Neither standalone component entry has a side-effect list, so this blend entry is the only side-effect documentation available for either compound on this site.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
One of the two compounds in this pill, sold on its own. Read it if you want to run the two separately, or for the cycling rules on that half.
The ERR-agonist component as a standalone at 300 mcg and 1,000 mcg per capsule, on a defined 4–8 week cycle with mandatory fasted dosing — both stricter than this blend page, which requires neither.
The other compound in this pill, sold on its own at the same 6 mg strength. Its protocol has a much slower build-up, starting at a quarter of a pill.
The GLP arm as a standalone at the identical 6 mg pill strength, but with a quarter-pill (1.5 mg) start and a titration running to 36 mg over 18–36 weeks. If GLP tolerability is the concern, that page's schedule is the gentler one.
Dosing figures have been reviewed and units are recomputed from the stated protocol.